Bevacizumab in Treating Patients With Angiosarcoma

Overview

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with angiosarcoma.

Full Title of Study: “An Open Label Multicenter Phase II Study of Bevacizumab for the Treatment of Angiosarcoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 6, 2013

Detailed Description

OBJECTIVES: Primary – Determine the median progression-free survival, in terms of stable disease, of patients with newly diagnosed or recurrent/refractory angiosarcoma treated with bevacizumab. Secondary – Evaluate the treatment effect of bevacizumab on the objective response rate as assessed by modified RECIST criteria in patients with angiosarcoma. – Evaluate the duration of response. – Assess the treatment effect of bevacizumab on duration of overall survival. – Explore the objective response by target tumor density changes on CT scan. – Evaluate the safety and tolerability of bevacizumab in patients with angiosarcoma. OUTLINE: This is an open-label, multicenter study. Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 to 4 months for 2 years. PROJECTED ACCRUAL: A total of 31 patients will be accrued for this study.

Interventions

  • Biological: Bevacizumab
    • Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).

Arms, Groups and Cohorts

  • Experimental: Bevacizumab
    • Bevacizumab treatment until disease progression or intolerance

Clinical Trial Outcome Measures

Primary Measures

  • Median Progression-free Survival of Patients Treated With the Study Drug as Defined by RECIST Criteria.
    • Time Frame: After cycles 2 and 4, then every 3 cycles thereafter while on treatment (1 cycle = 21 days); every 3-4 months after treatment up to 2 years.
    • During treatment, tumor assessment was done by MRI scan after the second cycle of study treatment, after the forth cycle of study treatment, and then every 3 cycles of treatment thereafter. After Study drug completion, tumor assessment by MRI was done every 3 to 4 months (for up to 2 years after the last bevacizumab dosage). Responses were categorized according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.

Secondary Measures

  • Objective Response Rate in Patients Treated With Bevacizumab.
    • Time Frame: After cycles 2 and 4, then every 3 cycles thereafter while on treatment (1 cycle = 21 days); every 3-4 months after treatment up to 2 years.
    • Objective response rate will be measured per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. Stable Disease, neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study. Progressive Disease, defined as having at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.
  • Duration of Response.
    • Time Frame: After cycles 2 and 4, then every 3 cycles thereafter while on treatment (1 cycle = 21 days); every 3-4 months after treatment up to 2 years.
    • During treatment, evaluation of response will be done by MRI scan after the second cycle of study treatment, after the forth cycle of study treatment, and then every 3 cycles of treatment. After Study drug completion, evaluation of response will be assessed by MRI every 3 to 4 months (for 2 years after the last bevacizumab dosage).
  • Assess the Treatment Effect of Bevacizumab on Duration of Overall Survival
    • Time Frame: After cycles 2 and 4, then every 3 cycles thereafter while on treatment (1 cycle = 21 days); every 3-4 months after treatment up to 2 years
    • After Study drug completion, assessment of treatment effect of bevacizumab on duration of overall survival will be assessed by MRI every 3 to 4 months (for 2 years after the last bevacizumab dosage).
  • Evaluate the Toxicity of Bevacizumab.
    • Time Frame: Day 1 of every cycle, on average every 21 days until end of treatment up to 2 years.
    • Toxicity data for bevacizumab will be collected on day 1 of every cycle (1 cycle = 21 days) during treatment according to the National Cancer Institute’s Common Toxicity Criteria for adverse events version 3.0 (CTCAE v3.0). In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE

Participating in This Clinical Trial

DISEASE CHARACTERISTICS:

  • Histologically confirmed angiosarcoma – Any stage disease – Must be deemed not surgically resectable (complete resection) and/or no other therapeutic modality is known to be curative – No angiosarcoma of a vessel wall – Newly diagnosed or recurrent/refractory disease – No prior tumor-related hemorrhage (any grade) – Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan – No CNS disease, brain metastases, or primary brain tumors PATIENT CHARACTERISTICS: – ECOG performance status of 0 or 1 – Absolute granulocyte count ≥ 1,500/mm^3 – Platelet count ≥ 100,000/mm^3 – Hemoglobin ≥ 9 gm/dL (transfusion and epoetin alfa allowed) – Creatinine ≤ 1.5 times upper limit of normal (ULN) – Urine protein:creatinine ratio ≤ 1.0 – Total bilirubin ≤ 1.5 mg/dL – Aspartate aminotransferase < 5 times ULN – Alkaline phosphatase < 5 times ULN – PT/INR ≤ 1.5 times ULN – PTT ≤ 1.5 times ULN – Fertile patients must use effective contraception – Ejection fraction > 49% for patients with prior anthracycline therapy, ischemic cardiac disease, or history of heart failure – No uncontrolled active infection – No uncontrolled high blood pressure (defined as > 150/100 mm Hg) – No symptomatic congestive heart failure (New York Heart Association class II-IV), unstable angina, cardiac arrhythmia, or myocardial infarction within the past 6 months – No psychiatric illness or social situation that would limit study compliance – No serious, nonhealing wound, ulcer, or bone fracture – No evidence of bleeding diathesis or coagulopathy – No clinically significant peripheral vascular disease – Not pregnant or nursing – No seizures not controlled with standard medical therapy – No embolic or hemorrhagic stroke or prior transient ischemic attack – No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months – No significant traumatic injury within the past 6 weeks PRIOR CONCURRENT THERAPY: – No prior therapy with bevacizumab or other antiangiogenesis treatment – No major surgical procedure or open biopsy within the past 6 weeks – No more than 2 prior chemotherapy regimens – No fine-needle aspiration or core-needle biopsy or other minor surgical procedure within the past 7 days – No radiotherapy within the past 28 days – No concurrent chronic daily treatment with aspirin > 325 mg/day or nonsteroidal anti-inflammatory medications – No concurrent warfarin or any other anticoagulant (any dose) – No concurrent radiotherapy – No concurrent major surgery

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Northwestern University
  • Collaborator
    • Genentech, Inc.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Mark Agulnik, Principal Investigator – Northwestern University
  • Overall Official(s)
    • Mark Agulnik, MD, Principal Investigator, Northwestern University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.